Ken Ishii
26Patents
7h-index
32Co-inventors
69Inventor score
Filing activity: Feb 6, 2002 → Aug 25, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6977245B2 | Oligodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 57 | Expired |
| US7521063B2 | Multiple CPG oligodeoxynucleotides and their use to induce an immune response | Emerging Cross-Sectional Technologies | 28 | Expired |
| US7666674B2 | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo | Emerging Cross-Sectional Technologies | 25 | Expired |
| US8030285B2 | Oligodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 16 | Active |
| US7960356B2 | Oligodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 13 | Expired |
| US7919477B2 | Multiple CpG oligodeoxynucleotides and their use to induce an immune response | Emerging Cross-Sectional Technologies | 11 | Active |
| US8232259B2 | Multiple CpG oligodeoxynucleotide and their use to induce an immune response | Emerging Cross-Sectional Technologies | 10 | Active |
| US8227446B2 | Oligodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 5 | Active |
| US8894996B2 | Immunoadjuvant composition and use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US10202606B2 | Complex containing oligonucleotide having immunopotentiating activity and use thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US11058758B2 | TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same | Emerging Cross-Sectional Technologies | 1 | Active |
| US8846867B2 | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies | Chemistry; Metallurgy | 1 | Active |
| US8389495B2 | Olioodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 1 | Active |
| US12414988B2 | Th1-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same | Emerging Cross-Sectional Technologies | 0 | Active |
| US8741869B2 | Oligodeoxynucleotide and its use to induce an immune response | Emerging Cross-Sectional Technologies | 0 | Active |
| US9400279B2 | Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction | Emerging Cross-Sectional Technologies | 0 | Active |
| US12319727B2 | Exosome-targeted DNA vaccine | Chemistry; Metallurgy | 0 | Active |
| US12209115B2 | Exosome-targeted DNA vaccine | Chemistry; Metallurgy | 0 | Active |
| US12306171B2 | Method for detecting indicator of immune-related disease | Physics | 0 | Active |
| US11015202B2 | Complex containing oligonucleotide having immunopotentiating activity and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US9732107B2 | Method for producing beta-hematin crystal comprising step of heating | Chemistry; Metallurgy | 0 | Active |
| US11268098B2 | Non-aggregating immunostimulatory oligonucleotides | Emerging Cross-Sectional Technologies | 0 | Active |
| US9028843B2 | Malaria vaccine | Emerging Cross-Sectional Technologies | 0 | Active |
| US9056094B2 | Adjuvant | Human Necessities | 0 | Active |
| US8808712B2 | Malaria vaccine | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.